One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026;…
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026
12-week data from Phase 1 trial of MBX 4291, a dual GLP… [11395 chars]
Source: GlobeNewswire | Published: 2026-01-11T21:00:00Z
Credit: GlobeNewswire
